Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Menstrual suppression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Menstrual suppression. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2020-003973-23 Sponsor Protocol Number: 213831 Start Date*: 2021-06-29
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Mole...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) IE (Completed) PL (Trial now transitioned) NL (Trial now transitioned) FI (Completed) FR (Completed) BE (Completed) DE (Completed) IT (Prematurely Ended) ES (Ongoing) HU (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001232-11 Sponsor Protocol Number: 200622 Start Date*: 2016-11-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophi...
    Medical condition: severe hypereosinophilic syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004306-50 Sponsor Protocol Number: A4001050 Start Date*: 2007-04-23
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 HIV-1 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) BE (Completed) CZ (Completed) DE (Completed) PT (Completed) ES (Completed) NL (Completed) AT (Completed) GR (Completed) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003096-35 Sponsor Protocol Number: CORT125134-455 Start Date*: 2019-06-19
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
    Medical condition: Endogenous Cushing syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.0 10014698 - Endocrine disorders 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BG (Completed) AT (Completed) PL (Completed) ES (Ongoing) DE (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023783-41 Sponsor Protocol Number: E7080-G000-303 Start Date*: 2011-07-05
    Sponsor Name:Eisai Limited
    Full Title: A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I- Refractory Differentiated Thyroid Cancer
    Medical condition: 131I-refractory differentiated thyroid cancer (DTC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) DE (Completed) ES (Completed) PL (Completed) DK (Completed) AT (Completed) IT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005752-16 Sponsor Protocol Number: CR0207-22 Start Date*: 2008-03-03
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestroge...
    Medical condition: recurrent or advanced oestrogen and/or progesterone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006198 Breast cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004149-40 Sponsor Protocol Number: PH2/053 Start Date*: 2007-06-12
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with letrozole versus letrozole alone in post-menopausal women with recurrent, oestrogen and/or proge...
    Medical condition: recurrent oestrogen and/or progesterone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009323-11 Sponsor Protocol Number: Start Date*: 2009-10-14
    Sponsor Name:University of Oxford
    Full Title: A randomised controlled trial of natural versus hormone replacement therapy cycles in frozen embryo replacement IVF: a pilot study
    Medical condition: Infertility - specifically in those women intending to undertake a frozen embryo replacement treatment who have at least 3 embryos fozen in storage and who are planning a first or second frozen emb...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013429-40 Sponsor Protocol Number: CVAK694A2205 Start Date*: 2009-10-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, double-blind, placebo-controlled trial to determine the capacity of VAK694 to elicit long term immune tolerance when combined with subcutaneous allergen immunotherapy for the treatment ...
    Medical condition: Seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016357-17 Sponsor Protocol Number: AI463-189 Start Date*: 2010-12-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive Revised Pro...
    Medical condition: CHRONIC HEPATITIS B VIRUS,PEDIATRIC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) GR (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-005173-27 Sponsor Protocol Number: 0858A4-318-WW Start Date*: 2005-10-21
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A COMBINATION OF LEVONORGESTREL AND ETHINYL ESTRADIOL IN A CONTINUOUS DAILY REGIMEN IN SUBJECTS WITH PREMENSTRUAL DYSPHORIC DISO...
    Medical condition: Premenstrual dysphoric disorder (PMDD) affects 3% to 5% of menstruating women. PMDD is defined by markedly depressed mood, anxiety, and/or affective lability during the last week of the late lutea...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) FI (Completed) SE (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000587-23 Sponsor Protocol Number: MK-8591A-018 Start Date*: 2020-01-13
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bicte...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Ongoing) FR (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000177-72 Sponsor Protocol Number: 208090 Start Date*: 2019-08-14
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infe...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) FR (Completed) DK (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001908-42 Sponsor Protocol Number: V937-013 Start Date*: 2020-10-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors
    Medical condition: Advanced/metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) HU (Completed) DE (Completed) PL (Completed) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003597-10 Sponsor Protocol Number: MK-8591A-028 Start Date*: 2020-07-15
    Sponsor Name:MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.
    Full Title: A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Adolescents with HIV-1 Infection who are Virologically Suppressed, are >=12 to <18 Years ...
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002671-10 Sponsor Protocol Number: 203820 Start Date*: 2016-12-20
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A two-part trial to evaluate the safety, tolerability, clinical effect and systemic exposure potential of topically applied GSK2981278 ointment in subjects with plaque psoriasis
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006712-93 Sponsor Protocol Number: MK-1088-002 Start Date*: 2022-06-09
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
    Medical condition: Advanced/metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2016-000276-23 Sponsor Protocol Number: 201464 Start Date*: 2016-12-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis
    Medical condition: Systemic amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000586-20 Sponsor Protocol Number: MK-8591A-017 Start Date*: 2020-03-04
    Sponsor Name:Merck Sharp & Dohme LLC.
    Full Title: A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretr...
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000460-42 Sponsor Protocol Number: AK001-002 Start Date*: 2016-06-29
    Sponsor Name:Allakos, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis
    Medical condition: Moderate to severe nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Completed) NL (Prematurely Ended) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 09:36:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA